<DOC>
	<DOCNO>NCT02260154</DOCNO>
	<brief_summary>Prospective , multicenter , non-comparative , observational program design assess effectiveness 2-6 week treatment Duspatalin® 200mg BID change quality life patient post-cholecystectomy gastro-intestinal spasm</brief_summary>
	<brief_title>Effectiveness Duspatalin® Patients With Post-cholecystectomy Gastrointestinal Spasm</brief_title>
	<detailed_description />
	<mesh_term>Spasm</mesh_term>
	<mesh_term>Muscle Cramp</mesh_term>
	<mesh_term>Postcholecystectomy Syndrome</mesh_term>
	<mesh_term>Mebeverine</mesh_term>
	<mesh_term>Alverine</mesh_term>
	<criteria>Male female ≥ 18 year 65 year ; Patients suffer postcholecystectomy GIspasms last 3 month symptom onset least 6 month prior inclusion require surgical treatment ; Laparoscopic cholecystectomy 6 month 5 year enrollment ; Patients prescribe Duspatalin® ( mebeverine ) 200 mg BID ( bi die = twice day ) accordance approve local label ; Patient 's write authorization provide data program General specific contraindication Duspatalin® treatment accord local label ; Planned Endoscopic Retrograde Cholangiopancreatography ( ERCP ) and/or surgical treatment ; Being currently treat treated Duspatalin® within 6 week prior enter program ; Pregnancy lactation ; Other condition make patient participation impossible ( investigator judgment ) ; Previous enrollment present program ; Treatment antispasmodic , painmedication ( Nonsteroidal antiinflammatory drug ( NSAIDs ) , tramadol , etc . ) within 2 week prior inclusion observational study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Duspatalin</keyword>
	<keyword>mebeverine</keyword>
	<keyword>cholecystectomy</keyword>
	<keyword>gastrointestinal spasm</keyword>
	<keyword>abdominal pain</keyword>
	<keyword>dyspepsia</keyword>
	<keyword>antispasmodic</keyword>
</DOC>